Serum from patients with acetylcholine receptor antibody–positive myasthenia gravis triggers pathogenic changes in human myotube cells
Factors other than acetylcholine signal transmission inhibition may contribute to the pathogenesis of AChR antibody-positive MG. Further research is needed to clarify the pathways involved, potentially leading to more tailored pharmacotherapies.
Authors
- Hiroyuki Akamine
- Hiroto Abe (ORCID: https://orcid.org/0000-0003-2647-9825)
- Shota Miyake
- Yosuke Onishi
- Manato Yasuda
- Hideo Handa
- Koki Nagaoka
- Masayuki Baba (ORCID: https://orcid.org/0009-0005-7079-762X)
- Etsuko Ogaya
- Yuko Nakatake-Furuie
- Keisuke Tanaka
- Satoshi Kuwabara
- Akiyuki Uzawa
- Kenichi Serizawa
Institutions
- Chiba University (JP)
- Chugai Pharma (United States) (US)
- Toa Pharmaceutical (Japan) (JP)
Publication Details
- Journal
- Journal of Neuroimmunology
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1016/j.jneuroim.2026.578871
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00